• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Living Cell Technologies NTCell meets primary endpoint in Phase I/IIa Parkinson’s trial

June 6, 2017 By Sarah Faulkner

Living Cell TechnologiesLiving Cell Technologies (ASX:LCT) touted data today showing its NTCell cell therapy is safe 130 weeks after treatment in a Phase I/IIa Parkinson’s trial. The study’s primary endpoint was safety.

The trial, which enrolled and treated 4 patients, involved implanting 40 NTCell capsules into 1 side of the brain. The company reported that treatment with NTCell continues to show improvement in motor function in patients with Parkinson’s disease, as measured by the Unified Parkinson’s Disease Rating Scale.

1 patient in the study elected to be treated with deep brain stimulation.

Living Cell Technologies’ NTCell is a alginate-coated capsule that contains cells sourced from a herd of pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands. These neonatal porcine choroid plexus cells secrete cerebrospinal fluid and provide a range of factors that support nerve cell function and protective enzymes, according to Living Cell Technologies.

The company coats the choroid plexus cells with its Immupel technology to guard the therapy from an attack by the host’s immune system and eliminate the need for an immunosuppressive regimen.

After NTCell is implanted into a damaged site within a patient’s brain, NTCell acts as “a neurochemical factory” that produces CSF and secretes multiple nerve growth factors to promote growth and repair disease-induced nerve degeneration, according to the company. Living Cell Technologies also boasts on its website that NTCell could potentially clear away waste, including amyloids and proteins.

“The results to date certainly validate the Phase IIb dose ranging study in progress, in which higher doses of NTCell are implanted into the putamen on both sides of the brain and which includes a sham surgical-controlled placebo group,” principal investigator Dr. Barry Snow said in prepared remarks.

“As this initial trial of a low dose of NTCell was designed to measure safety, we are happy that the primary endpoint continues to be met,” CEO Ken Taylor added. “We are looking forward to the results of the larger Phase IIb study initiated this year which is designed to measure efficacy. This study will confirm the most effective dose of NTCell, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub-group.

“Our goal, subject to continued satisfactory data, remains to obtain provisional consent and launch NTCell as the 1st disease modifying treatment for Parkinson’s disease in 2018,” Taylor said.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants, Neurological Tagged With: livingcelltechnologies

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS